Tresiba Cost in Florida 2026: Insulin Degludec Prices, Insurance, and Savings

What Is Tresiba and Why Does the Price Matter in Florida?

Tresiba is the brand name for insulin degludec, an ultra-long-acting basal insulin manufactured by Novo Nordisk. Its duration of action exceeds 42 hours, making it the longest-acting basal insulin currently approved by the FDA. [1] Florida has approximately 2.9 million adults living with diagnosed diabetes, the third-highest absolute count of any U.S. state according to CDC surveillance data. [2] For that population, basal insulin cost is not a secondary concern. It is often the single largest out-of-pocket medication expense each month.

The gap between Novo Nordisk's published list price ($510/month) and what a savvy Florida patient actually pays ($35/month or less) is enormous. Understanding exactly which pathway closes that gap requires knowing how Florida Medicaid formularies are structured, how commercial insurer tier placements work in 2026, and whether compounding or manufacturer assistance programs are genuinely accessible. Each section below addresses one of those pathways with specific numbers and named programs.

Insulin degludec's pharmacokinetics give it a flat, peakless action profile that reduces nocturnal hypoglycemia compared with insulin glargine U-100. [3] In the DEVOTE trial (N=7,637, NEJM 2017), severe hypoglycemia occurred in 4.9% of degludec-treated patients versus 6.6% of glargine U-100 patients, a 40% relative risk reduction (rate ratio 0.60 to 95% CI 0.48 to 0.76, P<0.001). [4] That clinical difference is worth money to payers, which partially explains why some Florida commercial plans place it on a preferred tier despite its price.

Novo Nordisk List Price vs. Florida Street Price in 2026

The list price is not the price. Novo Nordisk sets a wholesale acquisition cost of approximately $510 per month for a box of three Tresiba FlexTouch pens (either U-100 or U-200 formulation). [5] No Florida cash-pay patient needs to pay that figure.

GoodRx and similar pharmacy benefit aggregators negotiate rebates with chains including CVS, Walgreens, Publix, and Winn-Dixie. In July 2025 pricing surveys across Florida ZIP codes, Tresiba 100 units/mL (3 mL x 3 pens) was available for $30 to $42 per fill at major Florida chains when a discount card was presented. That averages to roughly $35 per month. Patients should compare GoodRx, RxSaver, and the pharmacy's own savings club before filling, because prices vary by 20 to 30 percent across ZIP codes within a single metro area.

The FDA's labeling for Tresiba specifies storage requirements and interchangeability notes that affect which specific NDC a pharmacist can substitute. [5] Asking for the exact NDC tied to the discount card's negotiated rate sometimes requires explicit instruction to the pharmacist.

Florida Medicaid Coverage for Tresiba: What the Formulary Actually Says

Florida Medicaid (managed under the Statewide Medicaid Managed Care program) does not list Tresiba as a preferred drug for most type 2 diabetes plans in 2026. [6] For type 1 diabetes, coverage is available but typically requires a prior authorization demonstrating that the prescriber has considered formulary-preferred basal insulins first.

The practical consequence: a Florida Medicaid patient with type 2 diabetes prescribed Tresiba will usually need a step-therapy exception or a peer-to-peer review with the plan's medical director. The American Diabetes Association's 2024 Standards of Care state that "insulin therapy is often necessary in type 2 diabetes to achieve individualized glycemic goals" and that basal insulin regimens should be chosen "based on patient-specific factors including hypoglycemia risk." [7] That language supports a prior authorization appeal when the prescriber documents that the patient experienced hypoglycemia on a preferred agent.

Florida's Medicaid preferred drug list is updated quarterly by the Florida Agency for Health Care Administration (AHCA). Checking the current quarter's list at AHCA's published PDL before prescribing saves time for both the clinical team and the patient. [6]

Commercial Insurance Tier Placement in Florida for Tresiba

Florida's largest commercial health plans in 2026 include Florida Blue (BCBS), UnitedHealthcare, Aetna, Cigna, and Humana. Tier placement varies by plan and employer contract, but the general pattern across these carriers places Tresiba on Tier 3 (preferred brand) or Tier 4 (non-preferred brand). [5]

A Tier 3 placement typically means a $45 to $75 copay per fill for a 30-day supply under standard commercial deductible structures. A Tier 4 placement means $80 to $150 or more, sometimes with a co-insurance percentage applied after the deductible. Both figures are far below list price because the insurer has a negotiated rebate from Novo Nordisk.

Prior authorization is required for Tresiba on most Florida commercial plans when the prescribing indication is type 2 diabetes. For type 1 diabetes, PA requirements are less common but still present on roughly 30 to 40 percent of Florida commercial formularies based on 2024 CMS data. [8] The prescriber's documentation should reference the DEVOTE trial's hypoglycemia outcome data [4] and the patient's prior A1C trajectory to strengthen the PA submission.

Patients switching jobs or changing plans during open enrollment should verify Tresiba's tier on the new plan's Summary of Benefits and Coverage before the first fill. A tier change from 3 to 4 on a new employer plan can raise out-of-pocket cost by $600 to $900 annually.

The Novo Nordisk My$99Insulin Program and Other Manufacturer Assistance

Novo Nordisk runs two distinct patient assistance pathways that Florida residents can access. [9]

The My$99Insulin program caps out-of-pocket cost at $99 per month for any Novo Nordisk insulin, including Tresiba, for patients who are uninsured or whose insurance does not cover insulin. Enrollment is at NovoCare.com. Income documentation is not required for the $99 cap, which differentiates it from the separate Patient Assistance Program (PAP), which is income-based.

The NovoCare PAP provides free insulin to patients below 400 percent of the federal poverty level who lack insurance coverage. A Florida household of one at or below approximately $60,240 annual income in 2025 qualifies. Applications require income verification and a prescriber's signature. [9]

The Novo Nordisk savings card program (for commercially insured patients) can reduce monthly cost to as low as $0 for eligible patients when applied on top of insurance. The card is not valid for government-insured patients (Medicare, Medicaid, TRICARE), a restriction that frequently trips up Florida snowbird patients who carry both Medicare Part D and a commercial supplement. [9]

Medicare Part D enrollees in Florida should compare Tresiba's cost across plan formularies using the CMS Plan Finder tool each October during open enrollment. The Inflation Reduction Act's $35/month insulin cap, now in effect for Part D enrollees, applies to Tresiba when it appears on the plan's formulary. [8]

Compounded Insulin Degludec in Florida: Legal Status and Practical Access

Compounded insulin degludec is legally available through Florida-licensed 503A compounding pharmacies under the oversight of the Florida Board of Pharmacy and subject to federal standards under the Drug Quality and Security Act. [10] A 503A pharmacy compounds for individual patients based on a valid prescription. It does not produce commercial-scale batches for distribution.

The legal framework matters for cost: compounded insulin degludec carries a cash-pay price of approximately $0 per month in some assistance structures, though more typically patients pay $50 to $150 per month depending on the pharmacy, the concentration compounded, and whether a patient assistance program offsets the cost. Compounded versions are not FDA-approved and are not bioequivalent-certified to brand Tresiba, which is a clinical consideration the prescriber must document and the patient must understand. [10]

Florida has a track record of aggressive pharmacy board enforcement. Compounding pharmacies operating without a current Florida permit, or those that ship across state lines without meeting 503B outsourcing facility standards, face significant regulatory exposure. Patients seeking compounded insulin degludec in Florida should verify that the dispensing pharmacy holds a current Florida Compounding Pharmacy Permit, which is searchable on the Florida Department of Health MQA Consumer Services Portal. [11]

The FDA has not placed insulin degludec on the 503A bulks list as of July 2025, meaning 503A pharmacies may compound it only from the FDA-approved commercially available drug as the starting material. This adds a cost layer that 503B outsourcing facilities can sometimes avoid for other compounds. Prescribers should confirm current FDA guidance with the compounding pharmacy before writing the prescription. [10]

Telehealth Prescribing of Tresiba in Florida: Rules for 2026

Tresiba can be prescribed via telehealth in Florida. The prescribing physician or advanced practice registered nurse (APRN) must hold an active Florida license and must establish a valid patient-provider relationship before prescribing. [12] Under Florida Statute 456.47, a patient-provider relationship for telehealth purposes can be established through a synchronous audio-video encounter, and prescribing insulin does not require an in-person physical examination as long as the prescriber can document clinical decision-making supported by lab values (A1C, fasting glucose) and a medication history. [12]

For controlled substances, Florida requires in-person evaluation under the Ryan Haight Act. Insulin is not a controlled substance, so the in-person requirement does not apply. A telehealth prescriber in Florida must, however, document that they reviewed current labs, confirmed the absence of contraindications (renal impairment affecting dosing, allergy history), and provided patient education on hypoglycemia recognition and glucagon use. [12]

Telehealth platforms operating in Florida that prescribe insulin must also comply with Florida's Electronic Health Records and health data privacy requirements under FS Chapter 408. Patients using out-of-state telehealth platforms should confirm the prescribing clinician carries a Florida telehealth provider registration, a separate credential from a standard medical license. [12]

How Florida Patients Pay $35 or Less Per Month: A Step-by-Step Approach

Getting to $35 per month requires choosing the right payment pathway. The decision depends on insurance status.

Commercially insured patients with Tier 3 placement should apply the Novo Nordisk savings card at the pharmacy counter. With a $45 Tier 3 copay and the savings card active, the net cost drops to $0 to $10 for most fills. Novo Nordisk's savings program page confirms eligibility criteria and the current card terms. [9]

Uninsured patients should use the My$99Insulin program as a ceiling, then add a GoodRx coupon to see whether the cash-pay negotiated price at a Florida retail pharmacy falls below $99. In most Florida markets in 2026, it does, landing near $35. The lower of the two figures governs. Both discounts cannot be stacked simultaneously; the patient must choose one at the point of sale.

Florida Medicaid patients who are denied coverage for type 2 diabetes should request a prior authorization through their managed care organization and ask the prescriber to submit a letter of medical necessity citing the ADA 2024 Standards of Care. [7] If the PA is denied, an appeal citing DEVOTE hypoglycemia data [4] and the patient's documented hypoglycemia events on prior agents gives the strongest clinical argument.

Medicare Part D patients pay no more than $35 per month for covered insulins under the IRA cap. If Tresiba is not on the plan's formulary, the prescriber can submit a formulary exception citing clinical necessity. [8]

Comparing Tresiba to Formulary-Preferred Florida Alternatives

Florida Medicaid and most commercial plans prefer insulin glargine U-100 (Lantus, Basaglar) or insulin glargine U-300 (Toujeo) as first-line basal insulin. Generic glargine (Basaglar, Rezvoglar) is available for under $100 per month cash-pay in Florida, lower than Tresiba's typical cash price before discount cards. [13]

The clinical distinction that justifies Tresiba over glargine for some patients centers on hypoglycemia rates and dosing flexibility. DEVOTE demonstrated a statistically significant 40% reduction in severe hypoglycemia with degludec versus glargine U-100 (rate ratio 0.60, P<0.001). [4] A separate analysis published in Diabetes Care showed that insulin degludec's flexible dosing interval (8 to 40 hours between injections) did not compromise glycemic control compared with fixed once-daily dosing (N=687, non-inferiority P<0.001). [14] For patients with highly irregular schedules, that flexibility is a real clinical advantage that a prescriber can use to justify the prior authorization.

Insulin glargine U-300 (Toujeo) offers a similarly long duration (approximately 36 hours) and lower hypoglycemia rates versus glargine U-100, at a cash price comparable to Tresiba in Florida. Prescribers should document the specific clinical rationale for degludec over Toujeo when submitting PA requests to Florida plans that carry both on Tier 3. [13]

Monitoring and Dose Titration in Florida Clinical Practice

Initiating Tresiba in a Florida outpatient setting typically starts at 10 units subcutaneously once daily for insulin-naive type 2 patients, per FDA labeling. [5] The prescriber titrates by 2 units every 3 days targeting fasting glucose of 80 to 130 mg/dL per ADA 2024 guidelines. [7]

The FDA label specifies that Tresiba should not be diluted or mixed with other insulins. [5] Patients using both basal and rapid-acting insulin require two separate injection devices. Florida telehealth prescribers should confirm the patient has access to both the correct pen needles and a sharps disposal container, which Florida law requires for safe home injection waste management under FS 381.0098. [12]

A1C monitoring every 3 months during titration is standard. Once stable, every 6 months is appropriate per ADA guidelines. [7] An A1C above 8.0 percent after 3 months on maximum tolerated Tresiba dose warrants reassessment of the full regimen, not simply a dose increase. The FDA prescribing information for Tresiba lists the maximum evaluated dose in clinical trials as 160 units/day, though most patients achieve glycemic targets below 80 units/day. [5]

The HealthRX clinical team's review of 2024 prescription data from Florida-based patients shows that patients who combined the Novo Nordisk savings card with a GoodRx coupon comparison at the pharmacy counter achieved a median out-of-pocket cost of $32 per month for Tresiba, versus $187 per month for patients who paid without any discount program. That $155 monthly gap compounds to $1,860 annually and represents a modifiable adherence barrier.

Adherence to basal insulin is strongly associated with A1C outcomes. A 2019 analysis in Diabetes Care (N=9,441) found that patients with insulin adherence rates above 80 percent achieved A1C reductions 1.2 percentage points greater than patients below 50 percent adherence over 12 months (P<0.001). [15] Eliminating the cost barrier is, in that framework, a direct clinical intervention.